3 Things You Need to Know
Standard of careIsn't working
You needIndividualized treatment
TimeIs of the essence
Nick: Patient Survivor
The day after his graduation from San Diego State University, Nick was diagnosed with a recurrence of his malignant meningioma. Nick knew he wasn’t going to have a lot of options, but we had just opened a Phase 0 clinical trial for this exact indication.
Tumors We Treat
As the Ivy Brain Tumor Center grows, every patient, regardless of diagnosis or stage of the brain tumor, will have the option to enroll in a Phase 0 clinical trial.
Common subtypes include astrocytoma, oligodendroglioma, glioblastoma, and gliosarcoma
Also known as ‘secondary’ brain tumors; originate from cancer in another part of the body
Primary brain tumors derived from the lining of the brain, known as the meninges
Arises from the ependymal cells that line the ventricles of the brain and the center of the spinal cord
Arises from small nests of cells near the pituitary stalk at the base of the skull, near the pituitary gland, third ventricle, and optic nerve
Occurs in the pineal region of the brain that may or may not involve the pineal gland
COMMUNITY OF CAREGIVERS
Ivy Brain Tumor Center Appoints Shwetal Mehta, Ph.D., as Chief Operating Officer
The Ivy Center has appointed Shwetal Mehta, Ph.D., as its chief operating officer. Dr. Mehta is a nationally recognized molecular neuro-oncologist who has distinguished herself as a rising star in brain tumor biology.
Ivy Brain Tumor Center and Vivace Therapeutics Collaborate to Test Targeted Agent in Glioblastoma and Meningioma
Ivy Brain Tumor Center has announced a new partnership with Vivace Therapeutics. This collaboration will allow researchers at the Ivy Center to evaluate a first-in-class TEAD inhibitor in glioblastoma and meningioma.
Ivy Brain Tumor Center and BridgeBio Pharma’s QED Therapeutics announce dosing of first patient in investigator-initiated Phase 0/2 clinical trial of infigratinib in recurrent glioblastoma
The Ivy Brain Tumor Center announced that the first patient has been dosed in an investigator-initiated Phase 0/2 clinical trial of infigratinib in recurrent high-grade glioma driven by FGFR genetic alterations. Infigratinib is an investigational, orally administered, FGFR1-3 selective tyrosine kinase inhibitor being developed by BridgeBio Pharma, Inc. (Nasdaq: BBIO) affiliate company QED Therapeutics, Inc.
Nurse who fought coronavirus in New York now battles his own brain cancer
Ian’s story has moved the country for his strength and selfless service on the COVID-19 frontlines in NYC. Now, facing a battle of his own, he’s turning to Dr. Nader Sanai and his team at the Ivy Brain Tumor Center and Barrow Neurological Institute to help him fight one of the most aggressive forms of brain cancer, glioblastoma.